Summary
Alnylam Pharmaceuticals, Inc. filed an 8-K on February 24, 2009, to report its financial results for the fourth quarter and full year ended December 31, 2008. This filing primarily serves to provide investors with the company's latest financial performance data, which was detailed in a press release furnished as an exhibit to this report. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release (Exhibit 99.1) for information regarding Alnylam's operational and financial condition as of and for the periods ended December 31, 2008. Investors should refer to this press release for specific details on revenue, expenses, net income/loss, cash position, and any forward-looking statements or strategic updates provided by management.
Key Highlights
- 1Alnylam Pharmaceuticals, Inc. announced its financial results for the Q4 and full year 2008 on February 24, 2009.
- 2The primary purpose of the 8-K filing is to disclose these financial results to the public.
- 3Detailed financial information is provided in the press release furnished as Exhibit 99.1.
- 4The filing indicates the company's performance and financial condition as of December 31, 2008.
- 5This report serves as a key update for investors on the company's financial standing.
- 6The information provided is furnished, not filed, meaning it's not subject to certain liabilities under the Exchange Act.